The Wall Street Journal: U.S. prosecutors accuse U.K.-based Indivior with fraud over opioid-addiction treatment

Federal prosecutors charged a U.K. pharmaceutical company with organizing a multibillion-dollar fraud to drive up sales of Suboxone Film, an opioid-addiction treatment.

As part of an indictment filed Tuesday in Virginia, the Justice Department said Indivior PLC INDV, +1.15%   set up a telephone and online program intended to connect callers with doctors that Indivior knew were prescribing Suboxone or opioids in a “careless and clinically unwarranted manner.”

The criminal charges come as the U.S. government has taken a more aggressive approach to fighting the opioid crisis, with thousands of lawsuits filed against opioid manufacturers and distributors.

In 2017, President Trump declared the opioid crisis a public health emergency and has taken steps to crack down on international and domestic drug-supply chains. The Justice Department is seeking at least $3 billion and control of other property from Indivior, previously the pharmaceuticals business of Reckitt Benckiser Group PLC. RB., +0.85%  

An expanded version of this story can be found at WSJ.com

Also popular on WSJ.com:

Patagonia triggers a market panic over new rules on its power vests

U.S. requires Texas Tech med school to end use of race in admissions decisions

Want news about Europe delivered to your inbox? Subscribe to MarketWatch’s free Europe Daily newsletter. Sign up here.

This post was originally posted at http://www.marketwatch.com/news/story.asp?guid=%7BD72FF83E-5B53-11E9-BFCF-FC5051E36806%7D&siteid=rss&rss=1.